Natera is trading 5.27% higher at $430.00, with no fresh company-specific catalyst confirmed for October 2, 2026. - The previously reported Japan regulatory filing remains under review; no new approval was confirmed. - The broader market is firmer ahead of U.S. jobs data, while biotech sector context is negative, so neither clearly explains the rise. - The move follows recent positive coverage, including RBC’s September 25 price-target increase, but that is not a confirmed overnight trigger.